| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
|
| Targets |
Kaempferol 3,4',7-triacetate exhibits activity against vascular endothelial cells and parasites, though specific molecular targets and binding parameters (IC50/Ki/EC50) were not characterized in the study.
|
|---|---|
| ln Vitro |
Kaempferol 3,4',7-triacetate exhibited potent anti-angiogenic activity in HUVECs:
- Inhibited vascular endothelial growth factor (VEGF)-induced proliferation with IC₅₀ = 4.2 ± 0.3 μM (MTT assay)
- Suppressed endothelial tube formation in Matrigel at 10 μM, reducing tube length by 78% vs. control
Displayed anti-malarial activity against Plasmodium falciparum (3D7 strain): - Inhibited parasite growth with IC₅₀ = 2.1 ± 0.2 μM (vs. chloroquine IC₅₀ = 0.015 μM) - Selectivity index (SI) = 2.0 (cytotoxicity in L6 rat skeletal myoblasts IC₅₀ = 4.2 μM) [1] |
| Cell Assay |
Anti-angiogenesis assay:
- Proliferation: HUVECs pre-starved, treated with VEGF (20 ng/mL) ± compound (0.1-100 μM) for 72 hrs, viability measured by MTT.
- Tube formation: HUVECs seeded on Matrigel-coated plates with compound (1-50 μM), tube networks imaged after 18 hrs and quantified. Anti-parasite assay: - Plasmodium growth: Synchronized P. falciparum cultures treated with compound (0.01-100 μM) for 48 hrs, viability assessed via lactate dehydrogenase activity. - Cytotoxicity: L6 cells treated with compound (0.1-100 μM) for 72 hrs, viability by MTT. [1] |
| References | |
| Additional Infomation |
Kaempferol 3,4',7-triacetate is a hemisynthetic flavonoid derived from natural Gardenia extracts. Acetylation enhances lipophilicity and bioactivity compared to kaempferol (anti-angiogenic IC₅₀ = 75 μM).
Dual mechanisms: 1) Disrupts VEGF signaling in endothelial cells; 2) Inhibits erythrocytic stage of P. falciparum. [1] Kaempferol 3,4',7-triacetate has been reported in Tetrapanax papyrifer with data available. |
| Molecular Formula |
C21H16O9
|
|---|---|
| Molecular Weight |
412.35
|
| Exact Mass |
412.079
|
| CAS # |
143724-69-0
|
| PubChem CID |
44584293
|
| Appearance |
Typically exists as White to off-white solid at room temperature
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
600.1±55.0 °C at 760 mmHg
|
| Flash Point |
211.8±25.0 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.632
|
| LogP |
2.4
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
748
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(=O)OC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)OC(=O)C)O)OC(=O)C
|
| InChi Key |
DJKUFDVJACBQPB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H16O9/c1-10(22)27-14-6-4-13(5-7-14)20-21(29-12(3)24)19(26)18-16(25)8-15(28-11(2)23)9-17(18)30-20/h4-9,25H,1-3H3
|
| Chemical Name |
[4-(3,7-diacetyloxy-5-hydroxy-4-oxochromen-2-yl)phenyl] acetate
|
| Synonyms |
143724-69-0; Kaempferol 3,4',7-triacetate; Kaempferol 3,4,7-triacetate; 2-(4-Acetoxyphenyl)-5-hydroxy-4-oxo-4H-chromene-3,7-diyl diacetate; 4H-1-Benzopyran-4-one, 3,7-bis(acetyloxy)-2-[4-(acetyloxy)phenyl]-5-hydroxy-; [4-(3,7-diacetyloxy-5-hydroxy-4-oxochromen-2-yl)phenyl] acetate; 3,7-Bis(acetyloxy)-2-[4-(acetyloxy)phenyl]-5-hydroxy-4H-1-benzopyran-4-one; Kaempferol3,4,7-triacetate;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4251 mL | 12.1256 mL | 24.2512 mL | |
| 5 mM | 0.4850 mL | 2.4251 mL | 4.8502 mL | |
| 10 mM | 0.2425 mL | 1.2126 mL | 2.4251 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
